The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-18 and is reviewed periodically as new material appears.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
=== 1973 === c. 20 April: Lynda Gough (19). The first sexually motivated killing the Wests are known to have committed together. Gough was a lodger at 25 Cromwell Street and shared sex partners with Rose. Following her disappearance, Gough's mother travelled to Cromwell Street to enquire about her daughter's whereabouts and saw Rose wearing her daughter's clothes and slippers. She was informed that Lynda had moved to find work in Weston-super-Mare. Lynda's remains were buried in an inspection pit beneath the garage, which was later converted into a bathroom. 10 November: Carol Ann Cooper (15). Cooper had been placed into care following her mother's death in 1966. She was last seen alive by her boyfriend in the suburb of Warndon boarding a bus to her grandmother's home. Fred referred to Cooper as "Scar Hand" in reference to a recent firework burn she had sustained. Cooper was the final victim unearthed from the cellar. Her skull was bound with surgical tape and her dismembered limbs bound with cord and braiding cloth. 27 December: Lucy Partington (21). Partington was an Exeter University student and the cousin of novelist Martin Amis. She was abducted from a bus stop along the A435. Her precise date of death may have been one week after her disappearance, as Fred admitted himself into the casualty unit of Gloucestershire Royal Hospital with a serious laceration of his right hand on 3 January, possibly sustained as he dismembered Partington's body. Her body was discovered in the Cromwell Street cellar on 6 March 1994.
=== Journal articles === Bridge, D; Cunningham, C W; Schierwater, B; DeSalle, R; Buss, L W (15 September 1992). "Class-level relationships in the phylum Cnidaria: evidence from mitochondrial genome structure". Proceedings of the National Academy of Sciences. 89 (18): 8750–8753. Bibcode:1992PNAS...89.8750B. doi:10.1073/pnas.89.18.8750. PMC 49998. PMID 1356268. Bridge, D; Cunningham, CW; DeSalle, R; Buss, LW (July 1995). "Class-level relationships in the phylum Cnidaria: molecular and morphological evidence". Molecular Biology and Evolution. 12 (4): 679–689. doi:10.1093/oxfordjournals.molbev.a040246. PMID 7659022. Fautin, Daphne Gail (October 2002). "Reproduction of Cnidaria". Canadian Journal of Zoology. 80 (10): 1735–1754. Bibcode:2002CaJZ...80.1735F. doi:10.1139/z02-133. hdl:1808/5373. Mackie, G O (October 2002). "What's new in cnidarian biology?". Canadian Journal of Zoology. 80 (10): 1649–1653. Bibcode:2002CaJZ...80.1649M. doi:10.1139/z02-138. Schuchert, P. (27 April 2009). "Phylogenetic analysis of the Cnidaria". Journal of Zoological Systematics and Evolutionary Research. 31 (3): 161–173. doi:10.1111/j.1439-0469.1993.tb00187.x. Kass-Simon, G; Scappaticci, Jr., A A (October 2002). "The behavioral and developmental physiology of nematocysts". Canadian Journal of Zoology. 80 (10): 1772–1794. Bibcode:2002CaJZ...80.1772K. doi:10.1139/z02-135. J. Zrzavý (2001). "The interrelationships of metazoan parasites: a review of phylum- and higher-level hypotheses from recent morphological and molecular phylogenetic analyses". Folia Parasitologica. 48 (2): 81–103.
=== HLX === Following the release of Half-Life: Alyx in 2020, dataminers examining updates to the Source 2 engine discovered that Valve was developing a non-VR game codenamed HLX. On December 31, 2024, Mike Shapiro, the voice actor for the G-Man, posted a cryptic message on X suggesting "unexpected surprises" in the new year. In April, it was reported that HLX was being playtested and would be a sequel to Episode Two. Industry insiders, dataminers and leakers reported that Valve was planning a 2025 announcement for HLX. In December, the Insider Gaming senior editor Mike Straw said HLX was planned as a launch game for Valve's Steam Machine hardware, and the announcement had been delayed by the rising cost of RAM.
Rl = Xwαl/wRw + (1 − Xw)αl/sRs, where Rl, Rw, and Rs are the DHRs of lipids, water, and substrates, respectively. Xw is the mole fraction of lipid H derived from external water, whereas αl/w and αl/s denote the net isotopic fractionations associated with uptake and utilization of water and substrate hydrogen, respectively. For phototrophs, Rl is calculated assuming that Xw = 1. The isotopic fractionation between lipids and methane (αl/m) is 0.94 for fatty acids and 0.79 for isoprenoid lipids. The isotopic fractionation between lipids and water (αl/w) is 0.95 for fatty acids and 0.85 for isoprenoid lipids. For plants and algae, the isotopic fractionation between lipids and methane (αl/m) is 0.94 for fatty acids and 0.79 for isoprenoid lipids.
Sources: en.wikipedia.org
In Natal, the Battle of the Tugela Heights, which started on 14 February was Buller's fourth attempt to relieve Ladysmith. The losses Buller's troops had sustained convinced Buller to adopt Boer tactics "in the firing line—to advance in small rushes, covered by rifle fire from behind; to use the tactical support of artillery; and above all, to use the ground, making rock and earth work for them as it did for the enemy." Despite reinforcements his progress was painfully slow against stiff opposition. However, on 26 February, after much deliberation, Buller used all his forces in one all-out attack for the first time and succeeded in forcing a crossing of the Tugela to defeat Botha's outnumbered forces north of Colenso. After a siege lasting 118 days, the Relief of Ladysmith was effected, the day after Cronjé surrendered, but at a total cost of 7,000 British casualties. Buller's troops marched into Ladysmith on 28 February. After a succession of defeats, the Boers realised that against such overwhelming numbers of troops, they had little chance and became demoralised. Roberts then advanced into the Orange Free State from the west, putting the Boers to flight at the Battle of Poplar Grove and capturing Bloemfontein, the capital, unopposed on 13 March with the Boer defenders escaping and scattering. Meanwhile, he detached a small force to relieve Baden-Powell. The Relief of Mafeking on 18 May 1900 provoked riotous celebrations in Britain, the origin of the Edwardian slang word "mafficking". On 28 May, the Orange Free State was annexed and renamed the Orange River Colony.
=== Mask squeeze === If a diver's mask is not equalized during descent the relative negative internal pressure can produce petechial hemorrhages in the area covered by the mask along with subconjunctival hemorrhages.
== NeuCode SILAC == Traditionally the level of multiplexing in SILAC was limited due to the number of SILAC isotopes available. Recently, a new technique called NeuCode (neutron encoding) SILAC, has augmented the level of multiplexing achievable with metabolic labeling (up to 4). The NeuCode amino acid method is similar to SILAC but differs in that the labeling only utilizes heavy amino acids. The use of only heavy amino acids eliminates the need for 100% incorporation of amino acids needed for SILAC. The increased multiplexing capability of NeuCode amino acids is from the use of mass defects from extra neutrons in the stable isotopes. These small mass differences however need to be resolved on high-resolution mass spectrometers.
=== South America === The effects of El Niño in South America are direct and strong. An El Niño is associated with warm and very wet weather months in April–October along the coasts of northern Peru and Ecuador, causing major flooding whenever the event is strong or extreme. Because El Niño's warm pool feeds thunderstorms above, it creates increased rainfall across the east-central and eastern Pacific Ocean, including several portions of the South American west coast. The effects of El Niño in South America are direct and stronger than in North America. An El Niño is associated with warm and very wet weather months in April–October along the coasts of northern Peru and Ecuador, causing major flooding whenever the event is strong or extreme. The effects during the months of February, March, and April may become critical along the west coast of South America, El Niño reduces the upwelling of cold, nutrient-rich water that sustains large fish populations, which in turn sustain abundant sea birds, whose droppings support the fertilizer industry. The reduction in upwelling leads to fish kills off the shore of Peru. The local fishing industry along the affected coastline can suffer during long-lasting El Niño events. Peruvian fisheries collapsed during the 1970s due to overfishing following the 1972 El Niño Peruvian anchoveta reduction. The fisheries were previously the world's largest, however, this collapse led to the decline of these fisheries.
Another strategy for site-specific amine conjugation to proteins is to replace lysine residues with arginine residues (LDVs). If all lysines are depleted then the only remaining free amine is at the amino terminus (N-terminus) of the protein. In the case where the protein is an antibody Fc domain, a recombinant LDV Fc can still be purified using protein A. LDV Fc proteins fused with short peptide targeting sequences can be used to deliver conjugated payloads, including nanoparticles, to specific cell surface proteins. The majority of ADCs under development or in clinical trials are for oncological and hematological indications. This is primarily driven by the inventory of monoclonal antibodies, which target various types of cancer. However, some developers are looking to expand the application to other important disease areas.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。